Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

127.26 +2.27 (+1.82%)
Streaming Delayed Price Updated: 12:53 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
68 69 Next >
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today ↗
 
Via Benzinga
News headline image
Time To Invest And Or Trade In Bio-Tech Stocks? ↗
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
News headline image
Why Gilead Sciences Stock Thrashed the Market Today ↗
In drug development, solid performance in large-scale clinical trials is crucial. 
Via The Motley Fool
News headline image
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections ↗
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by... 
Via Benzinga
News headline image
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention ↗
The company is trying to get ahead of a patent expiration for one of its key HIV prevention drugs. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
What the Options Market Tells Us About Gilead Sciences ↗
 
Via Benzinga
News headline image
Peering Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
Unveiling 10 Analyst Insights On Gilead Sciences ↗
 
Via Benzinga
News headline image
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
News headline image
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Four Stocks To Watch This Week - Monday, Sept 9 ↗
Inconsistent patchy behavior looks most likely in the very short term, but stocks still have decent potential in the medium term. Stay focused and be patient for the optimal setups near Key Levels. 
Via Talk Markets
News headline image
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment ↗
 
Via Benzinga
News headline image
Decoding Gilead Sciences's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today ↗
 
Via Benzinga
News headline image
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street ↗
Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging technical signals. 
Via Benzinga
News headline image
Biotech And Life Science Sector Update Summer Of 2024 ↗
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
News headline image
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats ↗
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. 
Via Investor's Business Daily
News headline image
Peering Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts ↗
 
Via Benzinga
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biotech Bull Market: 3 Ways To Play It ↗
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
News headline image
Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs ↗
Gilead Sciences exposes a major counterfeiting ring led by Peter Khaim, involving tampered HIV medications resold from New York pharmacies. The company seized over $750K in fake drugs, intensifying its... 
Via Benzinga
Topics Lawsuit
News headline image
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal ↗
FDA grants accelerated approval to Gilead's Livdelzi (seladelpar) for primary biliary cholangitis, offering new treatment options for patients with inadequate response to standard therapy. Continued... 
Via Benzinga
News headline image
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
From Gilead Sciences, Inc.
Via Business Wire
News headline image
7 Defensive Stocks to Buy as Investors Seek Shelter ↗
With the market primed for more jitters, investors should consider battening down the hatches with these defensive stocks. 
Via InvestorPlace
News headline image
3 Stocks Retirees Should Absolutely Love ↗
All of these stocks can provide steady income to retired investors. 
Via The Motley Fool
News headline image
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels ↗
Gilead Sciences' Q2 2024 revenue rose to $6.95B, beating expectations, driven by strong performance in HIV, Liver Disease, and Oncology. Adjusted EPS surged to $2.01, surpassing estimates, supported by... 
Via Benzinga
News headline image
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday? ↗
After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.